- Report
- February 2025
- 200 Pages
Global
From €4285EUR$4,490USD£3,590GBP
- Report
- February 2025
- 150 Pages
Global
From €4629EUR$4,850USD£3,878GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- October 2024
- 136 Pages
North America
From €3818EUR$4,000USD£3,199GBP
- Report
- August 2022
- 120 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- February 2024
- 182 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- November 2023
- 190 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- February 2024
- 103 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- March 2025
- 50 Pages
Global
From €2529EUR$2,650USD£2,119GBP
- Report
- November 2023
- 215 Pages
China
From €3818EUR$4,000USD£3,199GBP
- Report
- November 2023
- 109 Pages
China
From €1718EUR$1,800USD£1,439GBP
Captopril is a drug used to treat cardiovascular diseases, such as hypertension, congestive heart failure, and myocardial infarction. It is a prodrug, meaning it is converted into its active form, captoprilat, in the body. Captopril is an angiotensin-converting enzyme (ACE) inhibitor, which works by blocking the production of angiotensin II, a hormone that causes blood vessels to constrict. This helps to reduce blood pressure and improve blood flow.
Captopril is one of the most widely used cardiovascular drugs, and is available in both generic and branded forms. It is available in tablet, capsule, and liquid forms, and is usually taken once or twice daily. It is generally well-tolerated, but can cause side effects such as dizziness, headache, and nausea.
The captopril market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include Pfizer, Novartis, Merck, Sanofi, and GlaxoSmithKline. Show Less Read more